Stanford



Jake Scott, MD

Clinical Associate Professor, Medicine - Infectious Diseases

CLINICAL OFFICE (PRIMARY)

- **Stanford Health Care**

  5575 W Las Positas Blvd Ste 210

  Pleasanton, CA 94588

  Tel (925) 416-5430 **Fax** (925) 460-9002

Bio

BIO

Dr. Jake Scott is a board-certified infectious diseases specialist and Clinical Associate Professor in the Division of Infectious Diseases and Geographic Medicine at Stanford University School of Medicine. He serves as Medical Director of the Antimicrobial Stewardship Program and the Vascular Access Program at Stanford Health Care – Tri-Valley.

Dr. Scott provides inpatient and outpatient care for adults with a wide range of infectious diseases. His clinical interests include HIV care and prevention, antimicrobial stewardship, coccidioidomycosis, multidrug-resistant infections, recurrent urinary tract infections, and vaccines. His practice emphasizes compassionate, evidence-based care for patients from diverse backgrounds.

Dr. Scott is active in vaccine science communication and advocacy. As senior researcher for CIDRAP's Vaccine Integrity Project, he co-authored a comprehensive systematic review of COVID-19, RSV, and influenza vaccines published in the New England Journal of Medicine. He co-leads a collaborative database cataloguing more than 1,700 randomized controlled vaccine trials and has published on vaccine science in STAT News, CIDRAP, The Conversation, and other outlets. He has given over 100 media interviews with outlets including The New York Times, Washington Post, CNN, and NPR, and in 2025 testified before the U.S. Senate on vaccine science. He serves on the Board of Directors of Vaccinate Your Family.

His other academic work focuses on antimicrobial stewardship, diagnostic stewardship, and respiratory virus infections, with publications in JAMA, BMJ, and Nature Reviews Microbiology. He contributes to NIH-funded RECOVER and ACTIV-6 studies of COVID-19 and long COVID, writes monthly for Infectious Diseases Alert, and authored the BMJ Best Practice section on HIV-related opportunistic infections.

Dr. Scott was born and raised in the Bay Area and was inspired to pursue medicine after working as an HIV test counselor in San Francisco. He studied literature and creative writing in college and values the narrative aspect of medicine and the importance of listening carefully to each patient's story. He regularly teaches Stanford residents and students.

Outside of work, Dr. Scott enjoys rock climbing, surfing, and spending time with his two children.

CLINICAL FOCUS

- Infectious Disease

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Infectious Diseases

ADMINISTRATIVE APPOINTMENTS

- Vascular Access Program, Medical Director, Stanford Health Care Tri-Valley, (2025- present)
- Antimicrobial Stewardship Committee, Medical Director, Stanford Health Care Tri-Valley, (2016- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Board Member, Vaccinate Your Family (2026 - present)
- Member, Infectious Disease Association of California (2025 - present)
- Member, European Society or Clinical Microbiology and Infectious Diseases (ESCMID) (2023 - present)
- Member, Infectious Diseases Society of America (2013 - present)
- Member, Society for Healthcare Epidemiology of America (SHEA) (2015 - present)

PROFESSIONAL EDUCATION

- Board Certification: Infectious Disease, American Board of Internal Medicine (2025)
- Fellowship, UCLA Infectious Diseases Fellowship , CA (2016)
- Residency: Kaiser Permanente Oakland Internal Medicine Residency (2014) CA
- Medical Education: University of Vermont College of Medicine (2011) VT

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research and scholarly work centers on vaccine evidence, antimicrobial stewardship, and diagnostic stewardship. I am interested in how clinical trial data and real-world studies can guide proportional, evidence-based use of vaccines, antibiotics, and common diagnostic tests.

In vaccine research, I co-authored a comprehensive systematic review of COVID-19, RSV, and influenza vaccines published in the New England Journal of Medicine, synthesizing data on safety and effectiveness across products and populations. I also collaborate on a large database of randomized vaccine trials designed to organize and synthesize evidence about vaccine performance across pathogens and platforms.

My stewardship work focuses on practical questions that arise in everyday clinical care. As Medical Director of the Antimicrobial Stewardship Program at Stanford Health Care – Tri-Valley, I work on interventions to optimize antibiotic selection and duration and to reduce unnecessary antimicrobial exposure. This includes projects examining the use of biomarkers such as procalcitonin and inflammatory markers like CRP and ESR, and how more thoughtful use of these tests can support better prescribing and less overuse.

I also participate in multicenter NIH-funded studies, including RECOVER and ACTIV-6, which provide large, rigorously collected datasets on COVID-19 outcomes and therapeutics. Earlier work has included reviews on HIV/HCV treatment, HIV-related opportunistic infections, and the role of biomarkers in individualizing antimicrobial therapy. Through data synthesis, stewardship projects, and collaborative trials, my overall goal is to make complex infectious diseases evidence more usable for clinicians and health systems.

Publications

PUBLICATIONS

- **Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort Study.** *JACC. Advances*
  Vogel, J. M., Jenkins, T., Cerda, M., Chen, H., Goldman, J., Katz, S. D., Patterson, T. F., Ashktorab, H., Bartram, L., Barua, S., Brim, H., Brown, J. P., Castro, et al
  2026; 5 (7): 102923

- **Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
  Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia Del Sol, I. T., Shah, N. S., Mehta, M., Quintero Cardona, et al
  2026

- **Impact of Rapid Vancomycin Target Attainment**
  Mao, V., Lu, B., Scott, J.
  OXFORD UNIV PRESS INC.2026: S399

- **Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.** *The New England journal of medicine*
  Scott, J., Abers, M. S., Marwah, H. K., McCann, N. C., Meyerowitz, E. A., Richterman, A., Fleming, D. F., Holmes, E. J., Moat, L. E., Redepenning, S. G., Smith, E. A., Stoddart, C. J., Sundaram, et al
  2025

- **Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.** *JAMA network open*
  Horwitz, L. I., Becker, J. H., Huang, W., Akintonwa, T., Hornig-Rohan, M. M., Maranga, G., Adams, D. R., Albers, M. W., Ayache, M., Berry, J., Brim, H., Bryan, T. W., Charney, et al
  2025; 8 (9): e2533815

- **Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.** *JAMA internal medicine*
  Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia Del Sol, I. T., Ruiz-Unger, J., Shah, N. S., Mehta, et al
  2025

- **Evaluation of Procalcitonin-Guided Algorithm for Antibiotic Use in Lower Respiratory Tract Infections**
  Nguyen, A. K., Lu, B., Scott, J.
  OXFORD UNIV PRESS INC.2025: S909

- **Sex Differences in Long COVID.** *JAMA network open*
  Shah, D. P., Thaweethai, T., Karlson, E. W., Bonilla, H., Horne, B. D., Mullington, J. M., Wisnivesky, J. P., Hornig, M., Shinnick, D. J., Klein, J. D., Erdmann, N. B., Brosnahan, S. B., Lee-Iannotti, et al
  2025; 8 (1): e2455430

- **2024 Update of the RECOVER-Adult Long COVID Research Index.** *JAMA*
  Geng, L. N., Erlandson, K. M., Hornig, M., Letts, R., Selvaggi, C., Ashktorab, H., Atieh, O., Bartram, L., Brim, H., Brosnahan, S. B., Brown, J., Castro, M., Charney, et al
  2024

- **2024 Update of the RECOVER-Adult Long COVID Research Index** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
  Geng, L. N., Erlandson, K. M., Hornig, M., Letts, R., Selvaggi, C., Ashktorab, H., Atieh, O., Bartram, L., Brim, H., Brosnahan, S. B., Brown, J., Castro, M., Charney, et al
  2024

- **Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.** *JAMA network open*
  Rothman, R. L., Stewart, T. G., Mourad, A., Boulware, D. R., McCarthy, M. W., Thicklin, F., Garcia Del Sol, I. T., Garcia, J. L., Bramante, C. T., Shah, N. S., Singh, U., Williamson, J. C., Rebolledo, et al
  2024; 7 (10): e2439332

- **Revisiting Diagnostics: ESR and CRP: It's Time to Stop the Zombie Tests.** *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*

Spellberg, B., Nielsen, T. B., Phillips, M. C., Ghanem, B., Boyles, T., Jegorović, B., Footer, B., Mah, J. K., Lieu, A., Scott, J., Wald-Dickler, N., Lee, T. C., McDonald, et al
2024

- **Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.** *Annals of internal medicine*
  Erlandson, K. M., Geng, L. N., Selvaggi, C. A., Thaweethai, T., Chen, P., Erdmann, N. B., Goldman, J. D., Henrich, T. J., Hornig, M., Karlson, E. W., Katz, S. D., Kim, C., Cribbs, et al
  2024

- **Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.** *Viruses*
  Chu, C., Tao, K., Kouamou, V., Avalos, A., Scott, J., Grant, P. M., Rhee, S. Y., McCluskey, S. M., Jordan, M. R., Morgan, R. L., Shafer, R. W.
  2024; 16 (3)

- **Clinical course and management of COVID-19 in the era of widespread population immunity.** *Nature reviews. Microbiology*
  Meyerowitz, E. A., Scott, J., Richterman, A., Male, V., Cevik, M.
  2023

- **Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.** *JAMA*
  Stewart, T. G., Rebolledo, P. A., Mourad, A., Lindsell, C. J., Boulware, D. R., McCarthy, M. W., Thicklin, F., Garcia Del Sol, I. T., Bramante, C. T., Lenert, L. A., Lim, S., Williamson, J. C., Cardona, et al
  2023

- **Use of biomarkers to individualize antimicrobial therapy duration: a narrative review.** *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*
  Scott, J., Deresinski, S.
  2022

- **Covid-19 vaccines, immunity, and boosters.** *BMJ (Clinical research ed.)*
  Richterman, A., Scott, J., Cevik, M.
  1800; 375: n3105

- **Covid-19 vaccination: evidence of waning immunity is overstated** *British Medical Journal*
  Scott, J., Richterman, A., Cevik, M.
  2021

- **Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, northern California, USA, March–April 2020** *Emerging Infectious Diseases*
  Ferguson, J., Rosser, J., Quintero, O., Scott, J., Subramanian, A., Gumma, M., Rogers, A., Kappagoda, S.
  2020

- **Recurrent Multifocal Mycoplasma orale Infection in an Immunocompromised Patient: A Case Report and Review.** *Case reports in infectious diseases*
  Ketchersid, J., Scott, J., Lew, T., Banaei, N., Kappagoda, S.
  2020; 2020: 8852115

- **Treatment optimization for HIV/HCV co-infected patients.** *Therapeutic advances in infectious disease*
  Scott, J. A., Chew, K. W.
  2017; 4 (1): 18-36

- **Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Older Adults.** *Clinics in geriatric medicine*
  Scott, J., Goetz, M. B.
  2016; 32 (3): 571-83

- **Maternal decidual macrophages inhibit NK cell killing of invasive cytotrophoblasts during human pregnancy.** *Biology of reproduction*
  Co, E. C., Gormley, M., Kapidzic, M., Rosen, D. B., Scott, M. A., Stolp, H. A., McMaster, M., Lanier, L. L., Bárcena, A., Fisher, S. J.
  2013; 88 (6): 155

PRESENTATIONS

- COVID-19 Therapeutics Research Update - Stanford Medicine International COVID-19 Conference, Stanford University, speaker and panelist (5/15/2020)